Ph 1b Data for Tegavivint + Osimertinib combo in 1L EGFR-Mutated NSCLC Announced
“These promising results provide important early clinical evidence supporting tegavivint’s differentiated mechanism of action and its potential to address one of the fundamental limitations of targeted cancer therapy: the persistence of drug-tolerant tumor cells,” said Rahul Aras, Ph.D., President and Chief Executive Officer of Iterion Therapeutics. “We are particularly excited by the depth of tumor reduction, complete responses and survival observed in this study, together with the favorable tolerability profile of the combination. We believe these data provide important clinical validation for targeting β-catenin signaling and support the continued development of tegavivint in combination with targeted cancer therapies.”
Share:
More News
Jian Peng, PhD, CEO of Earendil Labs, said: “Genentech is a pioneer in defining modern biologics cancer medicine. Earendil Labs is building an AI-driven high-throughput biology platform that effectively integrates AI directly into biologics research and development—from predictive protein modeling and generative protein design to rapid experimental validation. By combining
“The IDMC’s recommendation to continue our Phase 2 MRD study without modification provides important independent validation of the favorable safety profile we have consistently observed across our clinical development program,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “Across our completed and ongoing clinical studies, we have
“These Phase 3 results reinforce the potential of ZENBEXUS to advance treatment for patients with relapsed or refractory multiple myeloma,” said Cristian Massacesi, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “As the first therapy in multiple myeloma to demonstrate superiority on an MRD-negative complete
“Initiating IND-enabling studies is a defining milestone for Beactica and for the BEA‑17 programme,” said Dr Per Källblad, Chief Executive Officer of Beactica Therapeutics. “With a first-in-class mechanism and compelling preclinical efficacy in combination with standard of care, we are now executing the rigorous safety and manufacturing programme that will